TLR-8 and TLR-9 antagonists, tested in an IL23 psoriasis mouse model, inhibited the Th1 and Th17 responses [15,16], and were active against psoriasis in a proof-of-concept trial [17]. The gene discussed is TLR8; the disease is psoriasis.